The final technical issue with which the committee grappled is which standard the mandatory compliance should apply to: should it be the 2012 shared standard, as envisaged by the bill, or the 2021 standard, which was published in New Zealand after the bill was introduced. The select committee naturally assumed it would be the latter, and that is reflected in clause 5(2) in the bill as reported back. Post select committee deliberation, it was brought to my attention that despite the updated standard being published in New Zealand, the Therapeutic Goods Administration of Australia has not yet adopted the 2021 standard or agreed transitional time frames. It makes sense to ensure whatever approach we take to mandating the joint standard is aligned with Australia, so I will introduce a Supplementary Order Paper in the committee of the whole House stage to return the mandated standard back to 2012. In discussions with Minister David Clark and his officials, who have been very supportive throughout this process, it was agreed that this was a sensible outcome, but the sector should be already moving to change their business processes to ensure compliance with the 2021 standard. I think I can say with confidence that it is highly unlikely that either the current Government or a future one would be open to any transitional arrangements to the 2021 standard that were beyond what Australian manufacturers already have.